TABLE 3.
Definitive therapy
| Patient category (no. of patients) and antibiotic | No. (%) of patients |
|
|---|---|---|
| Total | 30-day mortality | |
| MRVISA (59)a | ||
| Daptomycin | 33.9 (20) | 15 (3) |
| Ceftaroline | 28.8 (17) | 5.9 (1) |
| Linezolid | 20.3 (12) | 8.3 (1) |
| Telavancin | 11.9 (7) | 14.3 (1) |
| Doxycycline | 1.7 (1) | 0 |
| Quinupristin-dalfopristin | 1.7 (1) | 0 |
| Trimethoprim-sulfamethoxazole | 1.7 (1) | 0 |
| MSVISA (28) | ||
| Ceftriaxone | 35.7 (10) | 0 |
| Cefazolin | 25.0 (7) | 0 |
| Oxacillin | 14.3 (4) | 25.0 (1) |
| Linezolid | 7.1 (2) | 50.0 (1) |
| Vancomycin | 7.1 (2) | 100 (2) |
| Ceftaroline | 3.6 (1) | 0 |
| Daptomycin | 3.6 (1) | 0 |
| Trimethoprim-sulfamethoxazole | 3.6 (1) | 0 |
| MRSA (267) | ||
| Vancomycin | 55.1 (147) | 15.0 (22) |
| Ceftaroline | 19.9 (53) | 15.1 (8) |
| Daptomycin | 12.4 (33) | 9.1 (3) |
| Linezolid | 10.9 (29) | 37.9 (11) |
| Doxycycline | 1.1 (3) | 33.3 (1) |
| Trimethoprim-sulfamethoxazole | 0.4 (1) | 0 |
| Telavancin | 0.4 (1) | 0 |
a
MRVISA, methicillin-resistant vancomycin-intermediate Staphylococcus aureus.